Management of dyslipidemia after allogeneic hematopoietic stem cell transplantation

Dyslipidemia is one of the complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and it is often underestimated and undertreated. Dyslipidemia in allo-HSCT recipients has been confirmed to be associated with endocrine dysfunction, acute and chronic graft-versus-host dis...

Full description

Saved in:
Bibliographic Details
Published in:Lipids in health and disease 2022-08, Vol.21 (1), p.1-65, Article 65
Main Authors: Lu, Yingxue, Ma, Xiaojing, Pan, Jie, Ma, Rongqiang, Jiang, Yujie
Format: Article
Language:English
Subjects:
Age
Allogeneic hematopoietic stem cell transplantation
Bone marrow
Cardiovascular disease
Care and treatment
Child development
Cholesterol
Complications and side effects
Development and progression
Diabetes
Dyslipidemia
Dyslipidemias
Fatty acids
Glucose
Graft versus host disease
Graft versus host reaction
Hematopoietic stem cells
High density lipoprotein
Immunosuppressive agents
Insulin resistance
Lipids
Lipoproteins
Liver
Metabolic disorders
Metabolism
Pathogenesis
Population
Proprotein convertase subtilisin/Kexin type 9 (PCSK9)
Review
Risk factors
Statins
Stem cell transplantation
Transplantation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dyslipidemia is one of the complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and it is often underestimated and undertreated. Dyslipidemia in allo-HSCT recipients has been confirmed to be associated with endocrine dysfunction, acute and chronic graft-versus-host disease (aGVHD and cGVHD), immunosuppressive agent application, etc. However, few studies have illustrated the accurate molecular signaling pathways involved in dyslipidemia, and there are no standard guidelines for dyslipidemia management after HSCT. This review will discuss the pathogenesis of dyslipidemia, especially the association with aGVHD and/or cGVHD. Comprehensive treatment methods for dyslipidemia after HSCT will also be summarized.
ISSN:1476-511X
1476-511X
DOI:10.1186/s12944-022-01665-3